SSSandeep Soni

Sandeep Soni

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Sandeep Soni has a total of 15 co-authors. Here are the top co-authors by number of shared publications:

  • Thomas G. Gross

    Division of Hematology/Oncology/BMT; Nationwide Children's Hospital and Department of Pediatrics; The Ohio State University; Columbus Ohio

    2 shared publications
  • Alexandra Cheerva

    Division of Heme/Onc/BMT Kosair Children's Hospital University of Louisville Louisville KY USA

    1 shared publication
  • Andromachi Scaradavou

    Memorial Sloan-Kettering Cancer Center, Weill-Cornell School of Medicine; New York New York

    1 shared publication
  • Farid Boulad

    Memorial Sloan-Kettering Cancer Center, Weill-Cornell School of Medicine; New York New York

    1 shared publication
  • Hemalatha Rangarajan

    Division of Hematology/Oncology/BMT; Nationwide Children's Hospital and Department of Pediatrics; The Ohio State University; Columbus Ohio

    1 shared publication
  • Jueeli Dahake

    Department of Pediatrics; University of California, San Francisco School of Medicine; San Francisco California

    1 shared publication

Latest Publications

  • Combined umbilical cord blood and bone marrow from HLA-identical sibling donors for hematopoietic stem cell transplantation in children with hemoglobinopathies

    by Sandeep Soni, Farid Boulad, Morton J Cowan, Andromachi Scaradavou, Jueeli Dahake, Sandie Edwards, Mark C. Walters

    Background It is well established that umbilical cord blood and bone marrow are biologically different stem cell sources. Patients and Methods We analyzed the feasibility and outcome of hematopoietic stem cell transplantation (HSCT) in 13 children (median age 5.9 years) with hemoglobinopathies after the co- infusion of cord blood (CB) and bone marrow (BM) from the same human leucocyte antigen (HLA) identical sibling donor. We also compared outcomes of children with co-transplantation to outcomes in children with hemoglobinopathies who had received a BM (n = 21) or CB (n = 22) transplant alone. Results Compared to CB transplant (CBT) recipients, the co-transplant group had more rapid neutrophil (17 vs. 25 days, P = 0.013) and platelet (29 vs. 48 days, P = 0.009) recovery and less transplant related mortality. Patients who received a co-transplant had a lower incidence of ≥grade II acute (0% vs. 26.3%) and chronic (0% vs. 21%) graft versus host disease (GVHD) compared to BM transplant (BMT) recipients (P = 0.055 and 0.045, respectively). With a median follow-up of >60 months in each treatment group, the 5-year probability of event free survival (EFS) was 100% in the co-transplant group, 90% after BMT and 86% after CBT (P = 0.42). Conclusion Co-transplantation of CB and BM from HLA-identical sibling donors appears to be a feasible and effective strategy to further optimize outcomes of HSCT for hemoglobinopathies. Pediatr Blood Cancer 2014;61:1690–1694.


  • Outcomes of matched sibling donor hematopoietic stem cell transplantation for severe sickle cell disease with myeloablative conditioning and intermediate-dose of rabbit anti-thymocyte globulin

    by Sandeep Soni, Thomas G. Gross, Hemalatha Rangarajan, K. Scott Baker, Mollie Sturm, Melissa Rhodes

    Background Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative therapy for sickle cell disease (SCD) in children. Despite excellent outcomes of matched sibling donor (MSD) HSCT, there is still 5–10% chance of rejection and transplant related mortality (TRM) with 12–23% incidence of graft versus host disease (GVHD). We postulated that an intermediate dose of rabbit anti-thymocyte globulin (r-ATG, 10 mg/kg cumulative) would be effective in preventing both rejection and GVHD. Patients and Methods Fifteen patients, median age 5 (range 1.5–18) years, underwent MSD HSCT using busulfan (≥12.8 mg/kg with first dose pharmacokinetics), cyclophosphamide (total 200 mg/kg) and r-ATG. Bone marrow was the stem cell source; tacrolimus and methotrexate were given for GVHD prophylaxis. Results All patients achieved donor engraftment and there was no TRM. One patient rejected donor cells at 2 months post-transplant. Majority of the patients had high and sustained level of donor chimerism. None of the patients developed ≥Grade II GVHD. Incidence of CMV (10%) and EBV (9%) reactivations was low with rapid immune-reconstitution. Overall survival was 100% with event free survival of 93%. Conclusions Eliminating the risks of TRM and GVHD by optimizing the regimen may lead to further acceptance of HSCT for SCD. Pediatr Blood Cancer 2014;61:1685–1689.


  • Busulfan and melphalan as consolidation therapy with autologous peripheral blood stem cell transplantation following Children's Oncology Group (COG) induction platform for high‐risk neuroblastoma: Early results from a single institution

    by Sandeep Soni, Vinita Pai, Thomas G. Gross, Mark Ranalli

    Bu‐Mel as preparative therapy prior to autologous stem cell rescue was recently shown to be superior to the conventional CEM regimen for HR NBL in Europe. There are no data available on the feasibility and toxicity of Bu‐Mel as consolidation therapy following the COG‐type induction regimens used in North America. We report early complications and outcomes of patients with HR NBL who received Bu‐Mel for consolidation following COG‐based induction. Retrospective analysis of all patients who had received Bu‐Mel as preparative regimen prior to stem cell rescue for HR NBL was carried out. Toxicity, outcomes, and any delays to receiving radiation or anti‐GD2 antibody therapy were analyzed. Six patients undergoing PBSCT had received Bu‐Mel. The treatment was well tolerated. Mucositis was the main toxicity; three patients had developed neutropenia fever and none developed pulmonary toxicity. One patient had developed moderate SOS that responded to conservative management. All patients were able to receive and tolerate post‐transplant local radiotherapy and ch.14.18 anti‐GD2 antibody therapy without any delays. All patients are alive with no disease recurrence. The Bu‐Mel regimen is well tolerated and is feasible post‐COG‐type induction platform.


  • Successful unrelated umbilical cord blood transplantation for class 3 β‐thalassemia major using a reduced‐toxicity regimen

    by Sandeep Soni, Nancy Breslin, Alexandra Cheerva

    Unrelated umbilical CB transplant for class 3 β‐thalassemia major is associated with an increased risk of mortality and non‐engraftment. We describe two patients who underwent successful unrelated umbilical CB transplant using a novel reduced‐toxicity preparative regimen. This regimen may be sufficiently immunosuppressive and myeloablative to ensure engraftment with reduced risks of toxicity and mortality. Close monitoring of HHV‐6 viral load is advised for patients undergoing transplant with this regimen.